ASX:WFL Wellfully (WFL) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free WFL Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield4.56%Price TargetN/A Stock AnalysisStock Analysis Get Wellfully alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. About WellfullyWellfully Limited, together with its subsidiaries, engages in the research and development of Dermaportation and ETP transdermal drug delivery technologies. The company operates through two segments, Dermaportation Drug Delivery Technology and Devices. It is involved in the industrialization and supply-chain support for its existing product ranges; and sale and marketing of its own brands REDUIT and SWISSWELL, as well as third-party collaborations. It serves the pharmaceutical, cosmetic and skincare, and consumer healthcare sectors. The company was formerly known as OBJ Limited and changed its name to Wellfully Limited in September 2020. Wellfully Limited was incorporated in 1992 and is based in Leederville, Australia.Read More Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. WFL Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com Receive WFL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Wellfully and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolASX:WFL CUSIPN/A CIKN/A Webwww.wellfully.net Phone61 8 9443 3011FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-597.88% Return on Assets-133.07% Debt Debt-to-Equity Ratio79.21 Current Ratio0.58 Quick Ratio0.38 Sales & Book Value Annual Sales$1.51 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares492,940,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.91 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Paul PerosExecutive Chairman, MD & CEOMr. Blagojce PavlovskiCompany SecretaryMr. Sergej DolezilChief Financial OfficerDr. Matthew McIldowieChief Scientific OfficerKey CompetitorsANGLEOTCMKTS:ANPCYAustralian Clinical LabsASX:ACLBARD1 Life SciencesASX:BD1BCAL DiagnosticsASX:BDXbioAffinity TechnologiesNASDAQ:BIAFWView All Competitors This page (ASX:WFL) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJim Cramer’s “The Biggest Drug Ever”Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Wellfully Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
